This phase II trial tests how well giving botensilimab and balstilimab prior or to surgery (neoadjuvent) works for the treatment of colorectal cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that can be removed by surgery (resectable) colorectal cancer. Immunotherapy with monoclonal antibodies, such as botensilimab and balstilimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving botensilimab and balstilimab before surgery may make the tumor smaller. Giving neoadjuvant botensilimab and balstilimab may be effective for the treatment of advanced resectable colorectal cancer.

开始日期2026-12-27

申办/合作机构

City of Hope National Medical Center

[+1]

NCT07695311

/ Not yet recruiting临床1期IIT

Precision Analysis of Fusion Genes in Ewing Sarcoma (ES) and Desmoplastic Small Round Cell Tumor (DSRCT), Then EWSR1 (Ewing Sarcoma Gene Breakpoint Region 1 Gene) Immunotherapy Without or With Anti-CTLA-4 (Botensilimab) and Anti-PD1 (Balstilimab)

This study is for people who have high-risk Ewing sarcoma (ES), or a related Ewing's family tumor, desmoplastic small round cell tumor (DSRCT). The purpose of this study is to see if a new EWSR1 immunotherapy (a lipid nanoparticle coated with EWSR1 mRNA) which is given as a shot is safe and whether it can help the body's immune system better recognize and fight cancer.
This EWSR1 immunotherapy is designed to target a specific genetic change (EWSR1 fusion gene) that is found in cancer cells but not in normal, healthy cells. Because the EWSR1 gene is broken in cancer cells and the small protein it makes are only in the ES or DSRCT cancer cells, the goal of EWSR1 immunotherapy is to help the immune system identify and attack the cancer without harming normal cells. It is not yet approved by the Food and Drug Administration (FDA).
EWSR1 immunotherapy will be given as a shot into the muscle of the arm, leg, or buttock. If participants also receive botensilimab (4 doses after each EWSR1 immunotherapy shot) and balstilimab (an infusion every 2 weeks), these are given intravenously (IV) by a needle in the arm over 30 minutes. Participants in this study will receive treatment for about 6 months or until their cancer gets worse. Participants will remain in the study for follow-up for an additional year, for a total time of about 1.5 years in the study.

开始日期2026-10-01

申办/合作机构

The Case Comprehensive Cancer Center

NCT07516366

/ Not yet recruiting临床2期IIT

Pilot Phase II Trial Evaluating Safety and Feasibility of Neoadjuvant Botensilimab and Balstilimab in Clear Cell Renal Cell Carcinoma (NEO RoBOT)

This phase II trial tests the effect of botensilimab and balstilimab before surgery (neoadjuvant) in treating patients with high-risk clear cell renal cell cancer that has not spread from where it first started to other areas of the body (non-metastatic). The current standard treatment for patients with non-metastatic clear cell renal cell cancer may include surgery to completely remove the tumor. This typically involves removing the kidney or part of the kidney (nephrectomy). Immunotherapy with monoclonal antibodies, such as botensilimab and balstilimab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving neoadjuvant botensilimab and balstilimab may be safe, tolerable, and/or effective in treating patients with high-risk non-metastatic clear cell renal cell cancer before undergoing a nephrectomy.

开始日期2026-08-21

申办/合作机构

National Cancer Institute

100 项与 Botensilimab 相关的临床结果

登录后查看更多信息

100 项与 Botensilimab 相关的转化医学

登录后查看更多信息

100 项与 Botensilimab 相关的专利（医药）

登录后查看更多信息

482

项与 Botensilimab 相关的文献（医药）

2026-07-01·RESEARCH IN DEVELOPMENTAL DISABILITIES

Comparative effects of different types of exercise on improving motor impairments in children and adolescents with Autism: A network meta-analysis

Review

作者: Hou, Yaoqi ; Song, Xiangqin ; Lei, Zonghan ; Yan, Wang ; Deng, Zhicheng ; Feng, Mengyao

BACKGROUND:

Motor impairments are highly prevalent and clinically relevant in children and adolescents with ASD, yet the relative effects of different exercise modalities on motor function remain unclear.

METHODS:

We conducted an NMA of RCTs evaluating structured exercise interventions versus control in children and adolescents with ASD aged 3-18 years. Eligible trials included interventions lasting ≥ 4 weeks and reported standardized motor outcomes (e.g. TGMD/TGMD-2, BOT/BOT-2, MABC/MABC-2). Exercise programs were grouped into six modalities: CT, AS, BG, MSG, MBE and ES. A random-effects NMA was performed to estimate standardized mean differences (SMDs) and derive P-scores. Network heterogeneity and inconsistency were assessed using Q statistics and node-splitting. Small-study effects and potential publication bias were examined with funnel plots, Egger tests, trim-and-fill and selection models. Certainty of evidence was evaluated using CINeMA.

RESULTS:

Sixteen RCTs conducted in ten countries met the inclusion criteria. Exercise overall was associated with a moderate-to-large improvement in motor outcomes versus control (study-level pooled SMD 0.81, 95% CI 0.51-1.11). At the modality level, CT showed the largest benefit (SMD 1.10, 95% CI 0.61-1.60; P-score 0.81), followed by AS (SMD 0.69, 95% CI 0.34-1.10; P-score 0.78). BG (SMD 0.65, 95% CI 0.18-1.10; P-score 0.62; one trial) and MSG, MBE and ES (SMDs 0.23-0.47) showed small-to-moderate, statistically uncertain effects. Network heterogeneity and inconsistency were low, but funnel plots, Egger tests and selection models indicated small-study effects and potential publication bias, with bias-adjusted pooled SMDs decreasing to small-to-moderate magnitudes. CINeMA rated most comparisons as low or very low certainty, mainly due to within-study bias, reporting/publication bias and imprecision.

CONCLUSIONS:

Structured exercise appears to yield group-level improvements in motor outcomes in ASD, with CT and AS emerging as promising modalities in this NMA. However, the certainty of the underlying evidence is low, and small-study effects may inflate some estimates. These findings should be interpreted cautiously and considered hypothesis-generating; larger, rigorously reported RCTs with harmonised motor outcomes are needed to confirm or revise the current modality rankings.

2026-07-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Immunomodulatory effects of snake venom C-type lectins in vaccine formulations against ascariasis in mice

Article

作者: Lima, Joni Esrom ; Ruas, Ana Cristina Loiola ; Rihs, José Bryan ; Amorim, Chiara Cássia Oliveira ; Cardozo, Marcelo Eduardo ; Paloschi, Mauro Valentino ; Zuliani, Juliana Pavan ; Fujiwara, Ricardo Toshio ; Soares, Andreimar Martins ; Bueno, Lilian Lacerda ; de Oliveira, Ana Laura Grossi ; Ikenohuchi, Yoda Janaina ; de Lima, Anderson Maciel ; Souza, Jorge Lucas Nascimento ; Cirilo, Tatyane Martins

The search for novel vaccine adjuvants capable of enhancing or directing effective immune responses when combined with target antigens remains a global priority. Snake venom-derived biomolecules have previously demonstrated immunomodulatory activity in vitro, as reported in earlier studies, suggesting potential application as vaccine adjuvants. In this study, we evaluated the adjuvant potential of a C-type like lectin from Crotalus durissus terrificus (CVX) and a C-type lectin from Bothrops jararacussu (BjcuL) snake venoms in a murine immunization model using the recombinant BOT protein, previously described as immunoprotective against ascariasis. Mice received three immunizations at 10-day intervals and were subsequently challenged with Ascaris suum eggs. Formulations containing lectins enhanced the immunogenicity of BOT, inducing high levels of BOT-specific IgG. Although the BOT/CVX formulation elicited the highest antibody titers, only formulations containing MPLA or BjcuL significantly reduced parasite burden, whereas CVX did not confer protection and was associated with increased parasite load relative to the infected control. Endpoint analysis of circulating leukocytes and serum cytokines revealed that lectin-based formulations induced distinct immune profiles characterized by increased neutrophil frequencies and elevated IL-4 and IL-6 levels, while IL-2 was selectively increased in the CVX group. These findings highlight a dissociation between antibody magnitude and protective efficacy and indicate that BjcuL, but not CVX, displays adjuvant properties in this murine model of ascariasis. Collectively, this study supports the potential of selected snake venom lectins as vaccine adjuvants and emphasizes the importance of functional protection, safety evaluation, and mechanistic studies in future investigations.

2026-06-01·Internal and Emergency Medicine

Risk factors for oral and esophageal candidiasis during budesonide treatment in eosinophilic esophagitis patients

Article

作者: Ponziani, Francesca Romana ; Riccioni, Maria Elena ; Ianiro, Gianluca ; Spinelli, Irene ; Aruanno, Arianna ; Parmigiani, Maria ; Longhino, David ; Caruso, Cristiano ; Castri, Federica ; Fianchi, Francesca ; Gasbarrini, Antonio

Abstract:

Eosinophilic esophagitis (EoE) first-line therapy is represented by budesonide orodispersible tablets (BOT), but a very low number of patients develop oral and esophageal candidiasis. The aim of the study is to evaluate risk factors for the development of oral and esophageal candidiasis during budesonide therapy in EoE patients. A retrospective study was conducted to include all EoE patients in BOT therapy referred to our center. Prevalence, localization, and time of presentation of candidiasis, eosinophilic count in gastroscopy before BOT therapy, and concomitant treatment with proton pump inhibitors (PPI) and its dosage were reviewed. A total of 46 EoE patients in BOT therapy were included in the study. 7 patients (15%) developed oral and/or esophageal candidiasis. 4 patients (57%) of this group were in concomitant PPI therapy, all at 40 mg per day or more dosage, whereas 38% of patients without mycosis were taking this medication (41% at 40 mg per day or more). The mean eosinophil count before treatment was 45/HPF in patients with candidiasis infection and 33/HPF for the others without. Concomitant PPI therapy and high eosinophilic count may represent risk factors in developing mycosis in EoE patients.

257

项与 Botensilimab 相关的新闻（医药）

2026-07-15

·今日头条

索赔约10亿元，凯赛生物提起诉讼；昭衍新药上半年业绩大增

凯赛生物提起诉讼。 7月14日，凯赛生物公告称，公司及全资子公司凯赛(金乡)生物材料有限公司作为共同原告，以侵害技术秘密纠纷为由，向北京市高级人民法院起诉王志洲、葛明华、曹务波、山东瀚霖生物技术有限公司、陈远童、傅深展、中国科学院微生物研究所、山东归源生物科技有限公司、宁夏中科生物科技股份有限公司、宁夏中科生物新材料有限公司。公司诉请被告立即停止侵害原告技术秘密，销毁涉及“生物发酵法工业化生产长链二元酸技术”相关技术秘密的产线、设备、图纸，并连带赔偿经济损失约9.67亿元及合理开支100万元。目前案件已立案受理，尚未开庭审理。猴子涨价效应。 7月14日，昭衍新药公告称，预计2026年半年度归属于上市公司股东的净利润为6.00亿元-9.00亿元，同比增长884.9%-1377.4%。报告期内生物资产市场价格上涨叠加自身自然生长增值，双重因素驱动其公允价值正向变动，为公司业绩做出积极贡献。信达生物再出海。 7月14日，信达生物宣布，Spero将获得第三代抗CD40L单抗IBI355在大中华区以外的全球独家开发、研究、生产和商业化权益。信达生物将获得首付款，并有资格获得开发、注册及商业化潜在里程碑付款，交易总额约11亿美元；同时还将获得未来基于该产品净销售额的梯度式销售分成。在过去的一天里，国内外医药市场还有哪些热点值得关注？让氨基君带你一探究竟。 / 01 /市场速递 1）我国上半年创新药对外授权交易额超千亿美元 7月13日，新闻联播播报，今年1至6月，我国创新药对外授权交易总额约1100亿美元，达2025年全年总额的八成，再创历史新高。 2）迪哲医药与阿斯利康就舒沃哲®达成授权许可协议 7月14日，迪哲医药宣布，已与阿斯利康就舒沃哲®（舒沃替尼）达成授权许可协议。公司将授予阿斯利康在全球范围内的独家开发、商业化舒沃哲®的权利。 3）德琪医药收到优时比6000万美元首付款 7月13日，德琪医药宣布，已收到优时比支付的6000万美元首付款。该笔款项的支付依据为双方于2026年3月达成的CD19/CD3双特异性T细胞连接抗体ATG-201全球独家授权协议。 4）信达生物第三代抗CD40L单抗出海 7月14日，信达生物宣布，Spero将获得第三代抗CD40L单抗IBI355在大中华区以外的全球独家开发、研究、生产和商业化权益。信达生物将获得首付款，并有资格获得开发、注册及商业化潜在里程碑付款，交易总额约11亿美元；同时还将获得未来基于该产品净销售额的梯度式销售分成。 5）索赔约10亿元，凯赛生物提起诉讼 7月14日，凯赛生物公告称，公司及全资子公司凯赛(金乡)生物材料有限公司作为共同原告，以侵害技术秘密纠纷为由，向北京市高级人民法院起诉王志洲、葛明华、曹务波、山东瀚霖生物技术有限公司、陈远童、傅深展、中国科学院微生物研究所、山东归源生物科技有限公司、宁夏中科生物科技股份有限公司、宁夏中科生物新材料有限公司。公司诉请被告立即停止侵害原告技术秘密，销毁涉及“生物发酵法工业化生产长链二元酸技术”相关技术秘密的产线、设备、图纸，并连带赔偿经济损失约9.67亿元及合理开支100万元。目前案件已立案受理，尚未开庭审理。 / 02 /资本信息 1）昭衍新药预计上半年净利润同比增长885%-1377% 7月14日，昭衍新药公告称，预计2026年半年度归属于上市公司股东的净利润为6.00亿元-9.00亿元，同比增长884.9%-1377.4%。报告期内生物资产市场价格上涨叠加自身自然生长增值，双重因素驱动其公允价值正向变动，为公司业绩做出积极贡献。 / 03 /医药动态 1）中国生物制药BCL-2抑制剂拟纳入优先审评 7月14日，中国生物制药宣布，旗下公司正大天晴的BCL-2抑制剂TQB3909拟纳入优先审评，用于治疗既往经过至少包含BTK抑制剂在内的一种系统治疗的成人慢性淋巴细胞白血病/小淋巴细胞性淋巴瘤（CLL/SLL）。 2）劲方医药GFH375片获临床许可 7月14日，据CDE官网，劲方医药GFH375片获临床许可，联合GFH276或GFS202A治疗KRAS G12D突变阳性的晚期实体瘤患者。 3）天衡药物TH5910获临床许可 7月14日，据CDE官网，天衡药物TH5910获临床许可，拟开展治疗急慢性呼吸道疾病（如急慢性支气管炎、肺炎等）。 4）坦蒂生物Cizutamig注射液获临床许可 7月14日，据CDE官网，坦蒂生物Cizutamig注射液获临床许可，拟开展治疗系统性自身免疫风湿性疾病相关间质性肺病的研究。 / 04 /海外药闻 1）Agenus停止一项CTLA-4+PD-1组合III期临床 7月13日，Agenus宣布达成最高3.4亿美元的私募融资协议，并发布了一项重大的临床开发战略调整。根据披露，Agenus将停止对CTLA-4+PD-1组合疗法botensilimab和balstilimab（BOT+BAL）针对晚期转移性微卫星稳定（MSS）结直肠癌（CRC）的III期研究BATTMAN的财政支持；转而将资源集中在BOT+BAL组合在MSS结肠癌新辅助治疗的III期临床试验。

2026-07-14

·佰傲谷BioValley

Agenus：停止一项CTLA-4+PD-1组合III期临床

2026年7月13日，Agenus宣布达成最高3.4亿美元的私募融资协议，并发布了一项重大的临床开发战略调整。根据披露，Agenus将停止对CTLA-4+PD-1组合疗法botensilimab和balstilimab（BOT+BAL）针对晚期转移性微卫星稳定（MSS）结直肠癌（CRC）的III期研究BATTMAN的财政支持；转而将资源集中在BOT+BAL组合在MSS结肠癌新辅助治疗的III期临床试验。受这一重大战略计划的影响，Agenus股票应声上涨，截止当日收盘，上涨82.69%。终止的III期临床被停止的BATTMAN研究是一项对照、随机的全球性III期试验，旨在评估BOT+BAL组合治疗难治性、不可切除的微卫星稳定或错配修复功能完整型转移性结直肠癌。根据clinicaltrials.gov显示，BATTMAN于2026年3月31日注册，预计招募834名患者。2026年4月，该研究完成首位患者入组。该研究才进行3个月，就已经停止。实际上，在2024年7月，FDA就拒绝了BOT+BAL组合用于复发/难治性微卫星稳定型结直肠癌的加速批准。FDA指出，其组合疗法在该适应症的响应率并不总是能转化为生存率，希望Agenus能开展一项生存率的III期临床试验以证明该组合疗法对该群体患者的获益。当时，Agenus因资金问题搁置了即时的全面III期研究。不过，Agenus表示将继续追踪II期临床数据的同时，并继续努力说服FDA重新考虑以及寻求欧洲监管机构的批准。后来，Agenus还是启动了针对微卫星稳定型结直肠癌的III期研究BATTMAN，作为验证性研究，旨在支持BOT+BAL组合用于该适应症的潜在监管申报。目前，该III期临床已经停止。Agenus表示将履行对正在接受治疗的患者的所有义务，并与所有研究人员密切合作，负责任地管理这一过渡。同时，这也代表Agenus放弃了对BOT+BAL组合用于微卫星稳定型结直肠癌。集中资源搞MSS结肠癌在这次临床开发战略调整中，Agenus将BOT+BAL组合用于MSS结肠癌新辅助治疗作为优先级，本次融资的净收益将全部用于支持该项目，包括推动BOT+BAL组合用于MSS结肠癌新辅助治疗的III期研究ROBBIN。这主要是基于在两项独立的II期临床试验NEST和UNICORN中，BOT+BAL组合在MSS结肠癌新辅助治疗中展现出深度且持续的疗效：约60%-70%的患者实现病理缓解，30%达到病理完全缓解（pCR），且在中位随访9至18个月内无复发病例。此外，该治疗效果在NEST和UNICORN的更新中持续存在，Agenus公司表示更多细节将在今年晚些时候发布。这一优异的治疗效果，以及在治疗期间观察到的循环肿瘤DNA（ctDNA）清除率，极大支持了Agenus公司对于BOT+BAL组合用于MSS结肠癌新辅助治疗的信心。因此，Agenus公司停止了BOT+BAL组合针对晚期转移性微卫星稳定（MSS）结直肠癌（CRC）的III期研究BATTMAN的财政支持，将资源投入BOT+BAL组合用于MSS结肠癌新辅助治疗上。为此，Agenus计划启动名为ROBBIN的全球注册性III期试验，入组850名未经治疗的高风险II/III期MSS结肠癌患者，对比新辅助BOT+BAL联合标准治疗与单纯标准治疗的无事件生存期（EFS）。该试验设计已与FDA达成一致。根据Agenus公司披露的ROBBIN研究时间表：III期研究ROBBIN的首位患者服药预计在2027年第一季度完成，预计于2027年下半年完成中期病理反应数据，预计于2029年下半年完成EFS中期分析，预计2030年下半年完成EFS最终分析。小结实际上，Agenus最核心的研发方向就是CTLA-4与PD-1的肿瘤免疫治疗组合，同时也是该公司最知名的项目。但是Agenus的BOT+BAL组合仍未获得任何监管批准，此前Agenus主动撤回针对宫颈癌的BLA，以及FDA拒绝批准针对复发/难治性微卫星稳定型结直肠癌。参考资料： 1.https://www.businesswire.com/news/home/20260713089967/en/Agenus-Announces-Oversubscribed-Private-Placement-of-Up-to-%24340-Million-to-Advance-Registrational-ROBBIN-Trial-of-Neoadjuvant-BOTBAL-in-MSS-Colon-Cancer 2.https://clinicaltrials.gov/study/NCT07152821?term=BATTMAN&viewType=Card&rank=1

临床3期临床2期加速审批临床失败临床结果

2026-07-13

·新药猎人笔记

Agenus大涨82%！融资3.4亿美元开发CTLA4/PD-1组合CRC新辅助治疗

7月13日，免疫肿瘤学公司Agenus（NASDAQ: AGEN）宣布了一项重大的战略调整：停止对晚期转移性微卫星稳定型（MSS）结直肠癌III期BATTMAN研究的资金支持，将全部资源转向高风险早期结肠癌的新辅助治疗。与此同时，公司完成了一笔最高可达3.4亿美元的私募融资，受此消息提振，其股价周一盘中涨幅一度超过100%。根据公告，此次融资由Commodore Capital领投，RA Capital、TCGX及Ligand Pharmaceuticals等机构参投，包括8500万美元的即时到账资金，以及未来通过行使认股权证可获得的2.55亿美元。若权证全部行权，这笔资金预计可支撑公司运营至2031年底，足以覆盖关键临床数据的读出节点。战略重心转移的背后，是Agenus对管线价值的重新评估。此前在NEST和UNICORN两项II期研究中，其核心组合疗法botensilimab联合balstilimab（BOT+BAL）在MSS结肠癌新辅助治疗中展现出令人瞩目的疗效：约60%-70%的患者实现病理缓解，30%达到病理完全缓解（pCR），且在中位随访9至18个月内无复发病例。为此，Agenus计划启动名为ROBBIN的全球注册性III期试验，入组850名未经治疗的高风险II/III期MSS结肠癌患者，对比新辅助BOT+BAL联合标准治疗与单纯标准治疗的无事件生存期（EFS）。该试验设计已与FDA达成一致，首位患者预计于2027年一季度入组，中期病理缓解数据有望在2027年下半年公布。对于仍在接受BATTMAN试验治疗的患者，Agenus表示将继续履行相关医疗义务。公司CEO Garo Armen强调，聚焦新辅助治疗是基于现有临床证据强度和患者获益最大化做出的决定，旨在抓住这一长期未被满足的临床需求。结语：相比之下，晚期转移性MSS结直肠癌的治疗窗口竞争更为激烈，而新辅助治疗领域在过去20余年尚无突破性疗法获批，美国市场潜在年销售额超70亿美元。

临床2期临床3期突破性疗法并购引进/卖出

100 项与 Botensilimab 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
不能切除的大肠癌	临床3期	加拿大	Agenus, Inc.	2026-03-31
晚期癌症	临床3期	法国	Agenus, Inc.	2025-12-08
肝转移	临床3期	法国	Agenus, Inc.	2025-12-08
转移性胃腺癌	临床3期	法国	Agenus, Inc.	2025-12-08
肛门肿瘤	临床3期	荷兰	Agenus, Inc.	2024-01-29
食管鳞状细胞癌	临床3期	荷兰	Agenus, Inc.	2024-01-29
MSI-H 实体瘤	临床3期	荷兰	Agenus, Inc.	2024-01-29
微卫星稳定型直肠癌	临床2期	美国	Agenus, Inc.	2025-02-20
晚期结直肠腺癌	临床2期	-	City of Hope National Medical Center	2024-11-01
局部晚期直肠癌	临床2期	-	City of Hope National Medical Center	2024-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT07152821 (CO.33/BATTMAN, ASCO2026)	临床3期	不能切除的大肠癌	834	botensilimabbalstilimabb + botensilimabbalstilimab	壓蓋範顧齋鏇構襯鑰築(獵顧觸積繭簾餘壓廠蓋) = 構壓襯夢製製糧願觸壓膚艱艱窪鹽顧壓鏇夢遞 (窪構襯簾衊製蓋壓積糧 )	积极	2026-05-29
NCT05571293 (NEST-1 \| NEST, CTgov)	临床2期	错配修复缺陷或微卫星高度不稳定性结直肠癌 \| 直肠癌 \| 结肠癌 ... 更多	26	Botensilimab+Balstilimab (Cohort A: Botensilimab and Balstilimab (Bot/Bal))	顧製蓋衊鹹糧壓憲齋憲 = 選觸窪糧衊鹽膚願餘鹹繭壓選淵積簾構夢鹽鑰 (廠淵願壓鹹壓範構製觸, 觸齋選積遞網鑰製構選 ~ 選憲觸齋襯齋網鑰醖範) 更多	-	2026-05-22
NCT05571293 (NEST-1 \| NEST, CTgov)	临床2期	错配修复缺陷或微卫星高度不稳定性结直肠癌 \| 直肠癌 \| 结肠癌 ... 更多	26	Botensilimab+Balstilimab (Cohort B:)	顧製蓋衊鹹糧壓憲齋憲 = 醖繭糧獵顧築網齋糧顧繭壓選淵積簾構夢鹽鑰 (廠淵願壓鹹壓範構製觸, 夢衊鬱鹹艱繭繭鏇鑰鹹 ~ 鬱簾窪製鹽顧獵壓窪獵) 更多	-	2026-05-22
NCT03860272 (C-800-01, Company_Website) 人工标引	临床1期	晚期癌症	341	botensilimab+balstilimab	齋壓壓壓壓鏇鏇顧餘選(襯構範窪夢鑰顧淵窪繭) = 簾蓋繭膚願齋蓋網餘鏇鏇簾窪鹽願願觸夢鹽衊 (窪簾憲構壓衊衊蓋膚鏇 ) 更多	积极	2026-02-19
NCT03860272 (C-800-01, Company_Website) 人工标引	临床1期	晚期癌症	341	botensilimab+balstilimab (imAEs within the first 12 weeks)	窪淵鏇醖鏇構積淵夢窪(淵簾醖築壓廠餘齋憲醖) = 範襯夢蓋鹹觸築鏇選願艱獵廠餘廠憲襯觸範廠 (鬱製選繭淵窪淵鏇網醖 )	积极	2026-02-19
NCT05632328 (ASCO_GI2026)	临床2期	胰腺癌	10	botensilimab+AGEN1423	顧夢壓淵淵鏇壓蓋憲繭(鑰築獵構淵憲糧選遞顧) = 積製顧壓築積鏇襯積膚鏇鑰顧膚鬱夢膚鏇醖糧 (築製顧繭壓鑰鹹醖餘願, 3 ~ 65) 更多	积极	2026-01-08
NCT03860272 (C-800-01, J Immunother \| Company_Website) 人工标引	临床1期	难治性卵巢癌 \| 复发性铂耐药性卵巢癌	44	Botensilimab + Balstilimab	選遞夢獵構齋積齋選獵(獵膚積夢醖鹽鏇壓膚顧) = 餘鏇簾願簾糧窪鬱鏇範積繭鬱範觸鹽夢壓積積 (積醖構範築顧製淵鏇廠 ) 更多	积极	2025-12-23
NCT03860272 (ESMO2025)	临床1期	晚期恶性实体瘤	343	Botensilimab + Balstilimab (IO naïve)	遞顧範壓窪醖網繭壓鬱(餘鹹淵憲製鑰餘選範願) = 壓鑰衊獵蓋構獵襯膚鑰鹹艱鏇壓觸築鹽艱獵蓋 (製鹽製築鑰獵鹹齋積鏇 ) 更多	积极	2025-10-17
NCT03860272 (ESMO2025)	临床1期	晚期恶性实体瘤	343	Botensilimab + Balstilimab (IO refractory)	遞顧範壓窪醖網繭壓鬱(餘鹹淵憲製鑰餘選範願) = 蓋鹹壓窪鏇淵顧願壓築鹹艱鏇壓觸築鹽艱獵蓋 (製鹽製築鑰獵鹹齋積鏇 ) 更多	积极	2025-10-17
NCT03860272 (ESMO_GI2025)	临床1期	肝转移 \| 转移性微卫星稳定结直肠癌	123	Botensilimab 1 mg/kg + Balstilimab 3 mg/kg	窪獵鑰構糧衊鑰餘蓋鏇(鹹壓鏇鬱餘網蓋網窪獵) = 網築醖鹽範範蓋餘遞淵選醖積遞築蓋壓齋壓壓 (廠蓋鬱壓網遞鏇遞鹹壓, 48 ~ 66) 更多	积极	2025-07-03
NCT05608044 (ASCO2025)	临床2期	转移性结直肠癌 pMMR	10	Botensilimab monotherapy	膚獵鏇網範衊蓋構餘構(觸壓願餘壓襯製鹹壓齋) = 憲築衊鏇網廠壓膚壓願鹽鹹願願鏇鏇鏇襯顧鬱 (蓋製鏇糧選鬱醖鑰築遞 )	积极	2025-05-30
NCT03860272 (Phase 1 study of botensilimab and balstilimab, AACR2025)	临床1期	肝细胞癌	19	Botensilimab	獵遞構襯築獵簾製願鬱(構衊範積夢鑰夢顧願醖) = occurring in 37% of pts (16% G3) 衊廠築願窪艱鹹觸蓋餘 (齋鏇夢憲繭顧窪窪襯醖 ) 更多	积极	2025-04-29
NCT03860272 (Pubmed \| J Clin Oncol) 人工标引	临床1期	肉瘤	64	Botensilimab + Balstilimab	積壓獵築鏇襯衊獵製顧(糧觸築繭繭鏇鏇繭醖積) = The most common treatment-related adverse event (TRAE) was diarrhea/colitis occurring in 35.9% of patients, with grade 3 in 6.3% of patients. 構壓膚構艱網糧鹽簾窪 (憲夢糧鏇顧簾網積餘鹽 )	积极	2025-01-27
NCT03860272 (Pubmed \| J Clin Oncol) 人工标引	临床1期	肉瘤	64	Botensilimab + Balstilimab (angiosarcoma)		积极	2025-01-27